Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.

The conversation is about adding Swisse Hair Nutrition for Men, which contains saw palmetto and various vitamins, to a Minoxidil and finasteride regimen to potentially enhance hair growth. The user is seeking feedback on the effectiveness of stacking these supplements with their current treatment.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

User wants to add RCP to regimen and asks if it can be applied with topical minoxidil and/or finasteride at night.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

A user's experience with treating their hair loss using finasteride, minoxidil, RU58841, dermarolling, and nizoral; specifically discussing dosage levels of the medications and effects on libido.

The user is updating on their 3-month progress using minoxidil (0.5mg twice daily) and microneedling once a week. They plan to consult a doctor about adding finasteride to their regimen.

The user is pausing finasteride for blood donation and is concerned about its effect on DHT levels. They plan to supplement with saw palmetto and pumpkin seed oil during the pause.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The user is using finasteride and topical minoxidil for hair loss after previously trying them separately without success. They are experiencing a shedding phase but are committed to the treatment.

The user reports that their hair loss treatment with oral minoxidil, dutasteride, finasteride, topical minoxidil, ketoconazole shampoo, and microneedling has plateaued, with no significant additional regrowth. They have stopped using creatine to simplify their regimen and are relieved with the current state compared to before treatment.

Mixing ground finasteride pills with Minoxidil for topical use, with concerns about effectiveness and side effects. Users suggest using professionally formulated topical finasteride instead.

The user is using Minoxidil, Finasteride, microneedling, and plans to add low-level laser therapy (LLLT) to treat hair thinning. They shared progress pictures showing results from May 8th to June 7th.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

A user is experiencing hair loss in the center of their hairline and has been using topical finasteride for seven months with minimal progress. They are considering switching treatments due to concerns about losing ground and potential side effects of other options.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

The user is experiencing severe hair shedding despite using minoxidil, finasteride, ketoconazole shampoo, and dermarolling. They are considering changing treatments after stopping dermarolling and switching finasteride brands worsened the shedding.

The conversation discusses the effectiveness and value of a Locklabs pill containing finasteride, minoxidil, biotin, and a low dose of dutasteride for hair loss. The user is uncertain if the .1mg dutasteride dosage is sufficient and worth the cost.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

The conversation is about finding sources for topical anti-androgens like CB, pyrilutamide, fluridil, and aflatridol for hair loss treatment. The user is considering using CB powder from IndiaMart but is concerned about side effects from finasteride and minoxidil.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.